{
  "_metadata": {
    "description": "Historical screen failure rates by criterion type for patient funnel estimation",
    "last_updated": "2024-12",
    "sources": [
      "Published trial reports",
      "Industry benchmarks",
      "Site feasibility surveys",
      "Clinical trial databases"
    ],
    "notes": "Rates represent typical elimination at each criterion after prior criteria applied"
  },
  "oncology_phase3": {
    "description": "Phase 3 oncology trials",
    "average_screen_fail_rate": 0.35,
    "by_criterion_category": {
      "primary_anchor": {
        "description": "Disease indication + stage",
        "elimination_from_general_population": 0.99,
        "notes": "First filter, eliminates >99% of general population"
      },
      "demographics": {
        "age_restriction": {
          "typical_elimination": 0.05,
          "notes": "When age range is 18-75 or similar"
        },
        "gender_restriction": {
          "typical_elimination": 0.00,
          "notes": "Rarely a limiting factor except gender-specific cancers"
        }
      },
      "biomarker": {
        "description": "Genetic/molecular markers",
        "typical_elimination": 0.70,
        "notes": "Varies widely by biomarker frequency, e.g., EGFR+ (~15% have it, so 85% eliminated)"
      },
      "treatment_history": {
        "prior_lines": {
          "first_line": {
            "typical_elimination": 0.30,
            "notes": "Many patients have already received treatment"
          },
          "second_line_plus": {
            "typical_elimination": 0.40,
            "notes": "Requires specific prior therapy exposure"
          }
        },
        "washout_periods": {
          "typical_elimination": 0.10,
          "notes": "Recent treatment within washout window"
        }
      },
      "functional": {
        "ecog_status": {
          "ecog_0_1": {
            "typical_elimination": 0.20,
            "notes": "~20% of cancer patients are ECOG 2+"
          },
          "ecog_0_2": {
            "typical_elimination": 0.08,
            "notes": "More permissive, ~8% are ECOG 3+"
          }
        },
        "lab_criteria": {
          "typical_elimination": 0.25,
          "breakdown": {
            "anc_ge_1500": 0.08,
            "platelets_ge_100k": 0.10,
            "creatinine_clearance_ge_60": 0.12,
            "bilirubin_le_1_5_uln": 0.08,
            "ast_alt_le_3_uln": 0.10
          },
          "notes": "Compound effect when multiple labs required"
        }
      },
      "safety_exclusion": {
        "cns_metastases": {
          "active_excluded": {
            "typical_elimination": 0.15,
            "notes": "~15% of advanced cancer patients have CNS involvement"
          },
          "treated_stable_allowed": {
            "typical_elimination": 0.05,
            "notes": "Only excludes active/symptomatic"
          }
        },
        "cardiac": {
          "qtc_prolongation": {
            "typical_elimination": 0.05,
            "notes": "QTcF > 470ms in women, > 450ms in men"
          },
          "lvef_below_50": {
            "typical_elimination": 0.08,
            "notes": "Requires echo/MUGA, often excludes CHF history"
          },
          "recent_mi_stroke": {
            "typical_elimination": 0.03,
            "notes": "Within 6-12 months"
          }
        },
        "infections": {
          "active_infection": {
            "typical_elimination": 0.05,
            "notes": "Requiring systemic treatment"
          },
          "hiv_positive": {
            "typical_elimination": 0.01,
            "notes": "Increasingly allowed if controlled"
          },
          "hepatitis_b_c": {
            "typical_elimination": 0.02,
            "notes": "Often requires testing, may allow treated/cleared"
          }
        },
        "autoimmune": {
          "active_autoimmune": {
            "typical_elimination": 0.05,
            "notes": "Requiring immunosuppression"
          }
        },
        "prior_immunotherapy": {
          "irAE_requiring_discontinuation": {
            "typical_elimination": 0.08,
            "notes": "Grade 3+ immune-related AE from prior IO"
          }
        }
      },
      "administrative": {
        "consent_capacity": {
          "typical_elimination": 0.02,
          "queryable": false,
          "notes": "Rare, non-queryable"
        },
        "compliance_concerns": {
          "typical_elimination": 0.05,
          "queryable": false,
          "notes": "Investigator judgment"
        },
        "geographic_access": {
          "typical_elimination": 0.10,
          "queryable": false,
          "notes": "Distance to trial site"
        }
      }
    }
  },
  "oncology_phase2": {
    "description": "Phase 2 oncology trials",
    "average_screen_fail_rate": 0.40,
    "notes": "Generally more restrictive than Phase 3",
    "adjustments": {
      "biomarker_selection": "+10%",
      "ecog_restriction": "+5%",
      "notes": "Phase 2 often requires specific biomarker, tighter ECOG"
    }
  },
  "oncology_phase1": {
    "description": "Phase 1 oncology trials",
    "average_screen_fail_rate": 0.45,
    "notes": "Most restrictive, requires good PS and organ function",
    "adjustments": {
      "ecog_0_1_strict": "+10%",
      "organ_function_strict": "+10%",
      "prior_treatments_exhausted": "+15%"
    }
  },
  "non_oncology": {
    "cardiology": {
      "average_screen_fail_rate": 0.30,
      "common_exclusions": {
        "recent_mi": 0.15,
        "uncontrolled_hypertension": 0.10,
        "renal_impairment": 0.08
      }
    },
    "immunology": {
      "average_screen_fail_rate": 0.35,
      "common_exclusions": {
        "active_infection": 0.10,
        "malignancy_history": 0.08,
        "live_vaccine_recent": 0.05
      }
    },
    "neurology": {
      "average_screen_fail_rate": 0.38,
      "common_exclusions": {
        "psychiatric_comorbidity": 0.12,
        "cognitive_impairment": 0.10,
        "concomitant_cns_drugs": 0.08
      }
    }
  },
  "cumulative_effects": {
    "description": "How multiple criteria compound",
    "model": "multiplicative",
    "example": {
      "scenario": "NSCLC Phase 3 with EGFR requirement, ECOG 0-1, standard labs",
      "steps": [
        {"criterion": "NSCLC diagnosis", "remaining": 1.0, "notes": "Starting with disease population"},
        {"criterion": "Stage IV", "remaining": 0.49, "notes": "~49% of NSCLC is Stage IV"},
        {"criterion": "EGFR mutation positive", "remaining": 0.074, "notes": "~15% of NSCLC"},
        {"criterion": "ECOG 0-1", "remaining": 0.059, "notes": "~80% of Stage IV have ECOG 0-1"},
        {"criterion": "Adequate labs", "remaining": 0.044, "notes": "~75% meet lab criteria"},
        {"criterion": "No CNS mets", "remaining": 0.037, "notes": "~85% without active CNS"},
        {"criterion": "Other exclusions", "remaining": 0.033, "notes": "~90% pass remaining"}
      ],
      "final_pool_per_1000_nsclc": 33
    }
  },
  "optimization_benchmarks": {
    "description": "Impact of relaxing common criteria",
    "opportunities": {
      "ecog_0_1_to_0_2": {
        "typical_increase": 0.15,
        "notes": "Allows ECOG 2 patients, adds ~15% to pool"
      },
      "creatinine_clearance_60_to_30": {
        "typical_increase": 0.10,
        "notes": "Allows moderate renal impairment"
      },
      "treated_cns_allowed": {
        "typical_increase": 0.10,
        "notes": "Allow stable/treated brain metastases"
      },
      "remove_age_cap": {
        "typical_increase": 0.05,
        "notes": "Remove upper age limit (e.g., 75)"
      },
      "allow_controlled_hiv": {
        "typical_increase": 0.01,
        "notes": "Minor impact but equity consideration"
      },
      "reduce_washout_period": {
        "typical_increase": 0.05,
        "notes": "Shorter washout from prior therapy"
      }
    }
  }
}
